Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Income towards Parent Company (2022 - 2025)

Historic Income towards Parent Company for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $42.0 million.

  • Indivior Pharmaceuticals' Income towards Parent Company rose 9090.91% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.0 million, marking a year-over-year increase of 13888.89%. This contributed to the annual value of $7.0 million for FY2024, which is 10555.56% up from last year.
  • According to the latest figures from Q3 2025, Indivior Pharmaceuticals' Income towards Parent Company is $42.0 million, which was up 9090.91% from $18.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Income towards Parent Company ranged from a high of $85.0 million in Q2 2023 and a low of -$329.0 million during Q4 2022
  • Its 4-year average for Income towards Parent Company is -$5.8 million, with a median of $45.0 million in 2025.
  • Data for Indivior Pharmaceuticals' Income towards Parent Company shows a peak YoY increase of 12066.87% (in 2023) and a maximum YoY decrease of 43880.6% (in 2023) over the last 5 years.
  • Indivior Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$329.0 million in 2022, then skyrocketed by 120.67% to $68.0 million in 2023, then plummeted by 69.12% to $21.0 million in 2024, then soared by 100.0% to $42.0 million in 2025.
  • Its last three reported values are $42.0 million in Q3 2025, $18.0 million for Q2 2025, and $48.0 million during Q1 2025.